Recombinant Prokaryotic Host Cell for O-Glycosylated Protein Production

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for O-glycosylation of therapeutic proteins in prokaryotes are inefficient, particularly in E. coli, where enzymes like O-GalNAc-T form inactive inclusions, and suitable donor substrates are not adequately provided, limiting the production of glycoproteins with desired properties.

Innovation Solution

A recombinant prokaryotic host cell expressing eukaryotic UDP-GalNAc:UDP-GalNAc polypeptide transferase and UDP-GlcNAc C-4 epimerase is used to efficiently O-glycosylate recombinant mammalian proteins, leveraging the host cell's endogenous UDP-GlcNAc as a precursor to produce O-glycosylated proteins or peptides with modified immunogenicity and pharmacological properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If eukaryotic UDP-GalNAc:UDP-GalNAc polypeptide transferase is expressed in E. coli, then O-glycosylation of therapeutic proteins can be achieved, but the enzyme forms inactive inclusions reducing productivity

Engineering Contradiction:
Improveenzyme activityVSAvoidglycosylation production efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by modifying expression conditions including temperature (shifting from 37°C to lower temperatures like 18-25°C), induction timing, and culture media composition to prevent inclusion body formation and maintain enzyme solubility and activity in E. coli hosts

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses chaperone proteins as intermediaries to assist in the proper folding of the eukaryotic UDP-GalNAc:UDP-GalNAc polypeptide transferase, preventing aggregation and inclusion body formation while maintaining enzyme activity in the prokaryotic host

Inventive Principle:
Principle #24Intermediary (Mediator)

2Ease of manufacture

If prokaryotic systems are used for glycosylation, then manufacturing simplicity is improved, but the complexity of providing suitable donor substrates increases

Engineering Contradiction:
Improveprocess simplicityVSAvoidsubstrate provision complexity
Core Design Contradiction:
Ease of manufactureVSDevice complexity

Solution Approach 1:

The patent implements self-service by engineering the prokaryotic host to autonomously produce the required UDP-GlcNAc donor substrate through endogenous metabolic pathways, eliminating the need for external substrate addition and simplifying the overall manufacturing process

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent applies preliminary action by pre-engineering the prokaryotic host cell with necessary metabolic pathways and enzymes to synthesize UDP-GlcNAc before the actual glycosylation process, ensuring substrate availability without complicating the manufacturing steps

Inventive Principle:
Principle #10Preliminary action

3Quantity of substance

If O-glycosylation is performed in prokaryotes, then production cost is reduced, but the precision of glycosylation sites is limited

Engineering Contradiction:
Improveproduction yieldVSAvoidglycosylation site specificity
Core Design Contradiction:
Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent applies local quality by engineering specific amino acid sequences (such as Serine-Threonine-Proline motifs) at target glycosylation sites to enhance the specificity and efficiency of O-glycosylation by the UDP-GalNAc:UDP-GalNAc polypeptide transferase in prokaryotic systems

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables efficient in vivo production of O-glycosylated proteins and peptides with prolonged serum half-life and improved immunogenicity, facilitating the preparation of therapeutic proteins and peptides with specific glycosylation sites, overcoming the limitations of existing methods by providing a robust and flexible glycosylation platform.

Implementation Method 1

A recombinant prokaryotic host cell expressing eukaryotic UDP-GalNAc:UDP-GalNAc polypeptide transferase and UDP-GlcNAc C-4 epimerase is used to efficiently O-glycosylate recombinant mammalian proteins, leveraging the host cell's endogenous UDP-GlcNAc as a precursor

Methodology Applied
Scientific EffectEpimerase enzymatic reaction: Enzyme

Implementation Method 2

O-GalNAc-T has been suggested to form inactive inclusions when expressed in E. coli. In this respect, improved methods for expression in prokaryotes are needed. Moreover, suitable donor substrates need to be provided to the above-described cells in order to synthesize glycoproteins

Methodology Applied
Scientific EffectGlycosyltransferase enzymatic reaction: Enzyme

Data Source

PatentUS9051593B2Recombinant prokaryotes and use thereof for production of O-glycosylated proteins
Publication Date: 2015.06.09 TRUSTEES OF DARTMOUTH COLLEGE THE

AI summary

The present invention embraces a recombinant prokaryotic host cell containing nucleic acids encoding an eukaryotic UDP-GaINAc:UDP-GaINAc polypeptide transferase and expressing an UDP-GIcNAc C-4 epimerase and methods for using the same to produce an O-glycosylated protein.